| Christine Grossnickel, PT | |
|
6410 Rockledge Dr, Nrh Regional Rehab - Suite 600, Bethesda, MD 20817-1809 | |
| (301) 581-8054 | |
| (301) 564-0284 |
| Full Name | Christine Grossnickel |
|---|---|
| Gender | Female |
| Speciality | Physical Therapist |
| Location | 6410 Rockledge Dr, Bethesda, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033272778 | NPI | - | NPPES |
| 240160ZD6T | Other | MD | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 18778 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christine Grossnickel, PT 6410 Rockledge Dr, Nrh Regional Rehab - Suite 600, Bethesda, MD 20817-1809 Ph: (301) 581-8054 | Christine Grossnickel, PT 6410 Rockledge Dr, Nrh Regional Rehab - Suite 600, Bethesda, MD 20817-1809 Ph: (301) 581-8054 |
News Archive
Generic drug makers released a study Thursday that found generic pharmaceuticals have saved the U.S. - through private prescriptions as well as Medicare and Medicaid - more than $1 trillion over 10 years.
A new study by scientists in the U.S. has found that red and blue foods are the best when it comes to fighting cancer.
American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System. The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical Industries Limited, a top 20 pharmaceutical company, for the development of its novel anti-cancer compound, RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.
› Verified 2 days ago
Morgane Caroline Gay, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 6410 Rockledge Dr Ste 301, Bethesda, MD 20817 Phone: 301-897-0357 Fax: 301-897-2148 | |
Laura Leigh Cooper, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9707 Old Georgetown Rd, Bethesda, MD 20814 Phone: 301-530-0500 | |
Mrs. Mary Sadaya-guillermo, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 10215 Fernwood Rd, #506, Bethesda, MD 20817 Phone: 301-530-1010 | |
Katherine Michael, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 6400 Goldsboro Rd Ste 340, Bethesda, MD 20817 Phone: 301-493-8884 | |
Dr. Brittne R. Jackson, PT, DPT, MPH Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9080 Beale Rd, Bethesda, MD 20889 Phone: 301-400-2316 | |
Jill Leslie Tender, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6410 Rockledge Dr, Suite 301, Bethesda, MD 20817 Phone: 301-897-0357 Fax: 301-897-2148 |